Dr. Weixiong Xia 夏伟雄
Chief Physician
Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of nasopharyngeal carcinoma, including radiotherapy and chemotherapy.
Dr. Xia is a Chief Physician and MD at Sun Yat-sen University Cancer Center, serving as a master’s supervisor. Focus areas include comprehensive treatment of nasopharyngeal carcinoma and management of distant metastases. Dr. Xia holds grants from the National Natural Science Foundation and Guangdong Health Department, and has published over 30 papers, including 15 SCI-indexed articles as first or corresponding author.
Professional roles
- Member, American Society of Clinical Oncology (ASCO)
- Member, European Society for Medical Oncology (ESMO)
Name order: in Chinese the family name comes first (Xia Weixiong). Papers usually list the name as Weixiong Xia or Xia W.
Selected publications
76 papers on PubMed matched by name and affiliation; 16 as first or senior author since 2016. Most recent first- or senior-author papers:
- Int J Cancer, 2026 (senior author): Systemic Inflammation Mediates the Association Between Plasma Epstein-Barr Virus DNA and Mortality in Metastatic Nasopharyngeal Carcinoma. PubMed 42834566
- Eur J Nucl Med Mol Imaging, 2026 (senior author): Multimodal glyco-lipid-EBVDNA signature prognostic model for individualized risk stratification of locally advanced nasopharyngeal carcinoma. PubMed 41656424
- Oral Oncol, 2026 (senior author): Development of a simplified scoring system for MRI-detected retropharyngeal lymph node features to optimize AJCC 9th edition N classification in nasopharyngeal carcinoma. PubMed 41421245
- Oral Oncol, 2024 (senior author): Short-term versus long-term metronomic adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: A propensity score-matched real-world study. PubMed 38936007
- Cancer Manag Res, 2024 (senior author): Efficacy and Safety of Re-Challenging PD-1 Inhibitors in Second-Line Treatment in Metastatic Nasopharyngeal Carcinoma Previously Treated with Chemotherapy and PD-1 Inhibitors. PubMed 39006377
- JAMA Oncol, 2022 (senior author): Effect of Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil on Failure-Free Survival for Patients With Stage IVA to IVB Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial. PubMed 35323856
- Clin Cancer Res, 2021 (first author): A Randomized Controlled Trial Comparing Two Different Schedules for Cisplatin Treatment in Patients with Locoregionally Advanced Nasopharyngeal Cancer. PubMed 34083231
- Radiother Oncol, 2020 (senior author): MRI-detected residual retropharyngeal lymph node after intensity-modulated radiotherapy in nasopharyngeal carcinoma: Prognostic value and a nomogram for the pretherapy prediction of it. PubMed 31931288
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion